FDA Approves Daraxonrasib: A New Targeted Therapy for Metastatic Pancreatic Cancer
The US Food and Drug Administration (FDA) approved daraxonrasib (Rasonque) in August 2026 to treat metastatic pancreatic cancer.
70-100 BALANCED · 40-69 MIXED · 0-39 LEANING.
BBC
The US Food and Drug Administration (FDA) approved daraxonrasib (Rasonque) in August 2026 to treat metastatic pancreatic cancer. Clinical trials showed the KRAS inhibitor doubled median survival from 6.7 to 13.2 months compared to standard chemotherapy. While 90% of patients saw halted tumor growth, experts caution the treatment is not a cure. The drug targets proteins driving cancer growth, though dermatologic toxicity is a common side effect. Pancreatic cancer is the third-deadliest cancer, with a 13.7% five-year survival rate.
Context
Pancreatic cancer is the third leading cause of cancer death in the United States. Its five-year survival rate is 13.7%. The disease accounts for approximately 3% of all cancer diagnoses and causes about 53,000 deaths annually in the United States. Patients with metastatic disease, which is cancer that has spread to other organs, face a prognosis where only about 3% survive five years.
A patient began treatment with daraxonrasib and reported in September 2026 that his tumors were developing resistance to the medication. The Food and Drug Administration (FDA) approved daraxonrasib, sold as Rasonque, in August 2026 for certain patients with metastatic pancreatic cancer. Before this approval, standard chemotherapy offered a median survival time of approximately 6.7 months.
Supportive perspectives
Clinical trials showed that daraxonrasib monotherapy increased median survival time for pancreatic cancer patients to 13.2 months. Standard chemotherapy resulted in a median survival time of 6.7 months. The New York Post reported these findings on November 20, 2026.
In a phase I/II trial of 61 participants, 90% experienced a halt in tumor growth. Over 60% of these patients saw their tumors shrink or disappear after treatment with daraxonrasib combined with chemotherapy.
Reports say that 76.6% of patients treated with daraxonrasib survived one year after starting therapy. This compares to a 40-45% one-year survival rate for patients receiving only chemotherapy.
Daraxonrasib acts as a KRAS inhibitor. It targets and deactivates specific mutations that drive tumor growth in most pancreatic cancers. Dr. Philip Philip stated that the drug disrupts cancer cell growth and proliferation by paralyzing a critical protein.
Critical perspectives
Clinical trials for daraxonrasib show that 86% of patients develop dermatologic toxicity. The New York Post reported on November 20, 2026, that 10% of these patients experience severe or Grade 3 reactions.
Medical experts stated on November 20, 2026, that daraxonrasib does not cure pancreatic cancer. The BBC reported on November 20, 2026, that the duration of the treatment's effectiveness remains unknown.
Former Senator Ben Sasse reported in September 2026 that his tumors were developing resistance to treatment.
Sources verified by Neutral
This story is built from the reporting below. Tap a source to read the original.
Get the full picture on the Neutral News app
Both sides of every story on one page, with a neutrality score on top. Follow stories as they unfold. On Android and iPhone.
Already installed? Open in the app